Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a revenue of 17.7 billion yuan in 2025, representing a year-on-year growth of 94.3%. The net profit attributable to shareholders was 8.48 billion yuan, with a remarkable year-on-year increase of 305.8% [4] - The company has entered a global collaboration with Pfizer for its self-developed PD-1/VEGF dual antibody, SSGJ-707, with a total transaction value exceeding 6 billion USD, including an upfront payment of 1.4 billion USD [5] - The company is experiencing a concentrated period of product approvals, with three new drugs launched and several products entering the NDA stage, which is expected to drive sustained growth [6] Financial Summary - In 2025, the company’s R&D expenses reached 1.52 billion yuan, a year-on-year increase of 14.6%, supporting the advancement of its innovation pipeline [4] - The financial resources of the company rose to 20.4 billion yuan by the end of 2025, with a debt ratio of 9.8%, indicating an optimized asset-liability structure [4] - The projected net profits for 2026, 2027, and 2028 are 2.31 billion yuan, 2.55 billion yuan, and 2.87 billion yuan respectively, with corresponding EPS of 0.9, 1.0, and 1.1 yuan per share [4][8]
三生制药（01530）：港股公司信息更新报告：创新研发与全球合作并行，持续构建新增长引擎